Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06

CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

Recall #: D-1343-2022
Affected scope: 7,872/30 count bottles
Initiated: July 28, 2022

Compiled from official public sources by the publisher. · Updated September 2026

Lupin Pharmaceuticals Inc. recalled Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Ph… - a moderate-severity action.

Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Ph… was recalled by Lupin Pharmaceuticals Inc. in August 24, 2022. Reason: CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.. Check the official notice for the remedy. Verify recall #D-1343-2022 with the FDA Drug before acting.

The recall

Lupin Pharmaceuticals Inc. issued this moderate-severity FDA Drug recall-CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity..

Moderate
severity level: Class II
classification: August 24, 2022
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1343-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06

Reason for recall

CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Terminated
Recall number	D-1343-2022
Date reported	August 24, 2022
Date initiated	July 28, 2022
Recalling firm	Lupin Pharmaceuticals Inc.
Firm location	Baltimore, MD
Affected scope	7,872/30 count bottles
Distribution	Product was distributed nationwide.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-1343-2022) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Rifampin Capsules, USP, 150 mg, 30 count HDPE bottles, Rx Only, Manufactured for Lupin Pharmaceuticals, Inc., Baltimore, MD, 21202 NDC: 68180-658-06. Recalled by Lupin Pharmaceuticals Inc.. Units affected: 7,872/30 count bottles.

Why was this product recalled? ▼

CGMP Deviations:OOS result was observed in 1-Methyl-4-Nitroso Piperazine (MNP) impurity.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on August 24, 2022. Severity: Moderate. Recall number: D-1343-2022.

Where was the recalled product distributed? ▼

Distribution: Product was distributed nationwide..

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

PF-Neostigmine Methylsulfate Injection, U… 2022-08-24 Trisodium Citrate 0.5% Solution, (0.5%/4L… 2022-08-24 PF-0.125% Bupivacaine HCl Injection, USP,… 2022-08-24 PF-Labetalol HCl Injection, USP, 20 mg/4 … 2022-08-24

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

M Hand Sanitizer Ethyl Alcohol Antiseptic… 2022-08-24 Acetaminophen Injection, 10 mg/mL, 1,000 … 2022-08-24 Azacitidine for Injection, 100 mg Lyophil… 2022-08-24 Fulvestrant Injection 250mg/5mL (50 mg/mL… 2022-08-24

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported August 24, 2022. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026